Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data by Klijn, Christiaan et al.
Published online 10 January 2008 Nucleic Acids Research, 2008, Vol. 36, No. 2 e13
doi:10.1093/nar/gkm1143
Identification of cancer genes using a statistical
framework for multiexperiment analysis of
nondiscretized array CGH data
Christiaan Klijn
1,2, Henne Holstege
1, Jeroen de Ridder
1,2, Xiaoling Liu
1,
Marcel Reinders
2, Jos Jonkers
1,* and Lodewyk Wessels
1,2
1Netherlands Cancer Institute, Division of Molecular Biology, Plesmanlaan 121 1066 CX Amsterdam and
2Delft University of Technology, Information and Communication Theory group, Faculty of Electrical
Engineering, Mathematics and Computer Science, Delft, The Netherlands
Received August 20, 2007; Revised December 7, 2007; Accepted December 10, 2007
ABSTRACT
Tumor formation is in part driven by DNA copy
number alterations (CNAs), which can be measured
using microarray-based Comparative Genomic
Hybridization (aCGH). Multiexperiment analysis
of aCGH data from tumors allows discovery of
recurrent CNAs that are potentially causal to
cancer development. Until now, multiexperiment
aCGH data analysis has been dependent on dis-
cretization of measurement data to a gain, loss or
no-change state. Valuable biological information is
lost when a heterogeneous system such as a solid
tumor is reduced to these states. We have devel-
oped a new approach which inputs nondiscretized
aCGH data to identify regions that are significantly
aberrant across an entire tumor set. Our method
is based on kernel regression and accounts for
the strength of a probe’s signal, its local genomic
environment and the signal distribution across
multiple tumors. In an analysis of 89 human breast
tumors, our method showed enrichment for known
cancer genes in the detected regions and identified
aberrations that are strongly associated with breast
cancer subtypes and clinical parameters. Further-
more, we identified 18 recurrent aberrant regions in
a new dataset of 19 p53-deficient mouse mammary
tumors. These regions, combined with gene expres-
sion microarray data, point to known cancer genes
and novel candidate cancer genes.
INTRODUCTION
Malignant transformation of normal, healthy cells is
strongly dependent on changes in the expression of
oncogenes and tumor suppressor genes. DNA copy
number alteration (CNA) is an important mechanism
through which tumor cells can modulate expression of
cancer genes. CNAs are a result of genomic instability,
which has been described as an enabling mechanism
of tumorigenesis (1). Aberrations range in size from
relatively small regions (<0.5Mb) to entire chromosomes
and the various mechanisms by which they arise are
unclear (2). Comparative genomic hybridization (CGH) is
a technique that is capable of measuring CNAs. The term
CGH was ﬁrst used for competitive hybridization of
diﬀerentially labeled DNA on metaphase chromosomes
(3) to measure CNAs.
Various microarray platforms have enabled high-
resolution genome-wide analysis of CNAs by array-
based CGH (aCGH) (4). Many diﬀerent platforms are
currently available for aCGH analysis, such as bacterial
artiﬁcial chromosome (BAC) clone (4), cDNA clone (5),
single nucleotide polymorphism (SNP) (6) and oligonu-
cleotide based platforms (7,8). Most of the platforms
sample the genome at speciﬁc positions with a certain
distance between the measurement points (probes). This
distance is referred to as the resolution of the platform.
Array CGH data generally consist of the log-ratios of
normalized hybridization intensities of ﬂuorescently
labeled DNA from disease versus 2n control samples
measured by the probes spotted on these microarrays.
Array-CGH has been used extensively in cancer
research (9) and careful analysis of CNAs can facilitate
cancer gene discovery (10,11). Various automated
methods have been described to analyze the results
obtained from aCGH measurements. They typically
either smooth the data and/or try to estimate the location
of the aberration by deﬁning ‘break-points’ at which the
CNA is deﬁned to start or end (12,13). This is always done
at the single tumor level and procedures which deﬁne
aberrations often rely on several parameter choices to ﬁnd
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parameters relate to biological reality. Recently, methods
to discretize aCGH data have been extended to include
states other than 1, 0 and  1 (13–15). However, these
methods do not provide a solid statistical framework to
identify CNAs that occur in a signiﬁcant fraction of the
tumors. Especially these recurrent regions may harbor
genes relevant for tumor development.
Three methods have been developed to perform
multiexperiment analysis to identify recurrent CNAs
within a group of tumor samples: CMAR (16), STAC
(17) and H-HMM (18), a hidden Markov Model (HMM)-
based algorithm. Of these, STAC and H-HMM provide
probabilistic outputs. Both STAC and CMAR suﬀer from
the fact that aCGH data have to be discretized into three
states (1, 0 and  1) before the method can be applied.
H-HMM uses continuous data as input, but still employs
three discrete states in its hidden model. CNAs are discrete
in nature on a single cell level, as gains and losses of
a region of DNA can occur only on a per-copy basis.
Although a method for single cell aCGH has recently been
published (18), most aCGH analyses are not performed on
single cells, but rather on a population of tumor cells
mixed with stromal components. This stromal compart-
ment will inﬂuence the signal measured by quenching the
true CNA level. Moreover, as solid tumors are known to
be heterogenic in nature and contain sub-populations of
clonally diverse cells (19), it is also safe to assume that not
all tumors cells will carry the same CNAs. This implies
that an aCGH measurement will measure a population of
CNAs present in the tumor sample. Apart from the fact
that there is no consensus regarding the best discretization
method to use, reducing a signal from such a hetero-
geneous population of CNAs to values of 1, 0 and  1
leads to loss of potentially valuable biological
information.
We have developed a statistical method for multi-
experiment aCGH analysis of nondiscretized aCGH data
capable of detecting statistically signiﬁcant aberrations of
varying size. To this end, we developed KC-SMART,
Kernel Convolution: a Statistical Method for Aberrant
Region deTection. This method employs kernel convolu-
tion (20) to perform locally weighted regression (21),
which produces a smoothed estimate of the CNAs.
This approach takes into account (i) the nondiscretized
strength of a clone; (ii) the strength of neighboring clones
in the same tumor, as well as (iii) the occurrence frequency
of this clone across all tumors in the dataset. Kernel
regression automatically corrects for the unequal distances
between the probes. KC-SMART allows analysis of both
small and large aberrations using diﬀerent values for the
width of the kernel function. This is important, as DNA
copy number aberrations have a large variation in size (2).
Using a published dataset of 89 sporadic breast tumors
(22) we ﬁnd that KC-SMART identiﬁes several aberra-
tions that correlate with breast cancer subtype and clinical
parameters. We also identify regions that are enriched
for known cancer genes.
Furthermore, KC-SMART performs better than STAC
(17), the only other statistically-based method currently
available. Using aCGH and expression data from a novel
dataset of 19 mammary tumors from a conditional mouse
model of sporadic breast cancer, we identify several cancer
genes, and we show that complex aberrations can be
analyzed by varying the width of the kernel function.
Finally, we propose several new cancer gene candidates
based on KC-SMART results.
METHODS
Human breast cancer dataset
aCGH data were used as acquired from the
Supplementary Data of Chin et al. (22). Preprocessing
and normalization was performed and described by Chin
et al. (22). Because no exact mapping information was
available for all clones in the Chin dataset, we gave the
clones a 3-bp length centered on the mapping position as
supplied by Chin et al. We removed all clones with more
than 50% missing values. We imputated the remaining
missing values using the averaged values of their two
positional neighbors. Probes mapped to the same area
were averaged and represented as a single clone.
This resulted in 2149 unique clones. Gene expression
data were also acquired from Chin et al. (Arrayexpress
accession number: E-TABM-158). Probes not mapping to
a single ENSEMBL ID were removed; probes mapping
to Y chromosome genes were removed. This resulted in
21 339 unique Aﬀymetrix probe measurements.
Mouse p53dataset
All BAC information was based on NCBI assembly 36
of the mouse genome. The platform used to analyze
the mouse DNA was a 3k mouse BAC platform (23).
Extraction of DNA, labeling and hybridization to the
array was performed as described by Chung et al. (23).
Dye-swaps were performed for all samples. The data were
normalized using median normalization. BAC clones
containing more than 10% missing values were deleted
from the dataset. The remaining missing values were
imputed using the values of their two positional neighbors.
Should the imputed BAC clone be the ﬁrst or the last on a
chromosome, it is imputed using the value of its remaining
neighbor. The preprocessing left 2895 BACs for analysis.
Gene expression analysis was performed on in-house 32k
mouse oligo arrays. Detailed methods can be found in the
Supplementary Data. The data were normalized using the
Rosetta error model. The oligos were BLASTed against
the mouse transcriptome as of May 2006. All oligos
targeting multiple genes were discarded. All positional
information of the target genes was acquired from the
NCBI assembly 36 of mouse. Genes for which no
positional information was available were discarded.
Genes containing more than 10% missing values were
discarded. Remaining missing values were imputed using
the gene average over the nonmissing values.
Preprocessing left 25809 oligos targeting 19104 unique
genes. p53 conditional knockout mouse aCGH data are
under submission at the GEO database, accession number
GSE7794. Gene expression data are deposited at the
Arrayexpress database accession number E-NCMF-6,
details are in the Supplementary Data.
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Both datasets were analyzed equally by permutation
analysis. The KC-SMART permutation analysis was
performed to create a null distribution, and peaks were
detected at P<0.05 (Bonferroni corrected for multiple
testing), for kernel widths: 6  =2, 4, 6, 8, 10, 12, 16, 20,
24, 30 and 40Mb. One thousand permutations were used.
The interpolation, as discussed below, was performed for
an interval [2, 40] Mb, with steps of 0.2Mb and was
only applied to the mouse dataset. MATLAB scripts used
for implementation of the method are available from
the authors upon request.
Scale spaceinterpolation
To be able to lower the computational load which
is required if the signiﬁcance threshold needs to be
determined for a large number of kernel widths, an
interpolation step was introduced for more detailed
analysis of the mouse dataset. The signiﬁcance level at
a certain P-value is determined for several diﬀerent kernel
widths employing the permutation approach outlined
earlier. Then, a model is ﬁtted to these data which
describe the signiﬁcance threshold as a function of the
kernel width. The function found to ﬁt the relationship
best was a modiﬁed power function:
  ¼ a   bwkernel þ c 1
where   is the signiﬁcance threshold for the given wkernel.
The coeﬃcients a, b and c are estimated using an iterative
procedure that minimizes the sum of squared errors using
randomized starting values. This function is then used to
determine the signiﬁcance threshold for all kernel widths
within the range of the original widths tested. This allows
a detailed examination of the ‘scale space’, which is
deﬁned as the signiﬁcant areas in the genome given
diﬀerent kernel widths.
Integration ofgene expression data
We correlated gene expression proﬁles of the genes
in these signiﬁcant regions with the CNA data. First
we tested the pair-wise correlation of BAC clones in a
signiﬁcant region. If the average pair-wise correlation
coeﬃcient exceeded 0.5, we averaged the BAC-signals
across all clones, resulting in a region BAC proﬁle,
capturing the average behavior of a BAC clone in the
aberration. This proﬁle was correlated with the gene
expression proﬁle of each of the genes in the same region.
We calculated a P-value of the correlation of each gene’s
expression proﬁle with the region BAC proﬁle using the
Students t-test. All genes that correlated at P<0.05
(Bonferroni corrected) were called signiﬁcantly correlated.
Cancer geneenrichment
The cancer gene census (CGC) list was retrieved from the
Internet (www.sanger.ac.uk/genetics/CGP/Census/).
Mapping information was retrieved from the Ensembl
database (www.ensembl.org) using the Biomart data
mining tool. Only genes with valid mapping information
were used. The genes described in the CGC were divided
according to their label ‘recessive’ or ‘dominant’. This
resulted in 275 unique dominant genes and 65 recessive
genes. Enrichment for genes labeled as dominant was
tested in gains and enrichment for genes labeled as
recessive genes was tested in losses. For enrichment
analysis of the genes in the Chin dataset, only those
genes with measured gene expression proﬁles were used
and only those genes with an ENSEMBL-gene identiﬁer.
This left 11 409 unique genes measured.
DAVID analysis
Genes found signiﬁcant by correlation were compiled into
gene lists according to method (KC-SMART, STAC) and
according to gain/loss status. Only genes with valid Entrez
and Ensembl IDs that were present on the gene expression
microarray platform were considered. As background,
gene list of all genes with Entrez and Ensembl Ids on the
array platform was used. Association with cancer was
calculated using the DAVID web interface (david.abcc.
ncifcrf.gov) and as described in ref. 24.
Discrete data
The raw data used for frequency analysis are described in
Chin et al. (22) and were segmented using the parameter-
free segmentation algorithm CBS (25) and assigned
copy number change using MergeLevels (13), courtesy of
J. Fridlyand. All positive copy number changes were
counted as gains (1); all negative copy number changes
were counted as losses ( 1) and no copy-number change
was set to 0.
Frequency analysis. For each BAC clone, the overall
frequencies of 1 (gains) and  1 (losses) were counted
and plotted as a percentage on its genomic location. For
comparison, frequencies of 30% and higher were chosen
to be signiﬁcant.
STAC analysis. STAC inputs data discretized to three
levels: 1, 0 and  1. The raw data used for frequency
analysis are described in Chin et al. (22) and were
segmented using the parameter-free segmentation algo-
rithm CBS (25) and assigned copy number change using
MergeLevels (13), courtesy of J. Fridlyand. All positive
copy number changes were counted as gains (1); all
negative copy number changes were counted as losses ( 1)
and no copy-number change was set to 0. We followed the
advice on the STAC website (cbil.upenn.edu/STAC/) and
divided each chromosome arm into stretches of 1Mb.
A stretch was called aberrant whenever a BAC clone
present in that stretch was called aberrant. Stretches
containing no BACs were set to 1/ 1 when both
neighbors were 1/ 1, 0 when one of them was 0. The
preprocessed data were loaded into the STAC 1.2 java
applet and analyzed using 1000 permutations and a 1-Mb
span constant. The OR regions were deﬁned by either the
frequency statistic or the footprint statistic being P<0.05.
The ‘AND’ regions were deﬁned by both the frequency
statistic and the footprint statistic being P<0.05.
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Array CGH data consist of the log-transformed ratios
of normalized intensities from case versus control
samples measured on certain positions on the genome.
In heterogeneous tumors, gains or losses do not assume
discrete amplitude values along the genome. To model the
fact that CNAs are manifested in a continuous manner in
an aCGH proﬁle of a tumor, we start oﬀ by producing
a smoothed estimate of the cross-tumor averaged genome-
wide CNAs proﬁle using kernel convolution (20).
Array CGH probes are not distributed equally across
the genome. This unequal probe spacing inﬂuences the
smoothed estimate and needs to be corrected for. To this
end, we employed a kernel convolution-based method
to perform locally weighted regression (21).
A schematic overview of the KC-SMART method
is depicted in Figure 1. The general principle of
KC-SMART is to place a kernel function at the position
of each probe. At an arbitrary position x on the genome,
the kernel smoothed estimate (KSE) of the log2 ratio
is given by
KSEðxÞ¼
P
Mi ai   giðxÞ
P
Mi giðxÞ
2
Where ai is the sum of all positive or negative log2 values
across all tumors for probe i, gi(x) is the kernel function
Figure 1. A schematic overview of KC-SMART. T1, T2 and T3 represent three arbitrary tumor samples. (a) Illustration of the nature of the data
measured and how it is represented on the genome. The BAC clones are spaced along the genome where the sizes of the gaps depend on the platform
used. Per BAC clone a log2 value is measured that is a representation of the CNA at that point on the genome. (b) The positive and negative log2
values in the data are separated and summed across tumors and per BAC clone. After summation the kernel convolution is applied and the Kernel
Smoothed Estimate (KSE: blue line) is determined. (c) An overview for the method of determining statistical signiﬁcance is shown here. First, the
original log2 values are shuﬄed randomly within each tumor. After summation across tumors the KSE is computed. For both the gains and the
losses a cumulative density function (CDF) of the detected peaks is calculated. By testing the signiﬁcance level against this CDF a value is obtained,
above which peaks are found to be signiﬁcant. (d) Here the result of a genome-wide analysis is shown. The blue line is the KSE obtained from
the data and the red line is the signiﬁcance threshold at P=0.05, which was determined in (c). (e) The scale space is constructed by arranging
the signiﬁcantly aberrant areas (visualized as blocks) in order of scale on the genomic position.
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to the KSE. The denominator implements the locally
weighted regression to account for unequally distributed
clones.
Gains and losses are analyzed separately since gains and
losses are fundamentally diﬀerent (only a few copies of
a region can be lost, depending on the ploidy of the cell,
but many copies can be gained). The separation of gains
and losses also prevents positive and negative values from
summing to zero. Several kernel functions were considered
for constructing the KSE. A ﬂattop Gaussian kernel was
chosen since it remains constant across the length of the
BAC clone, and then drops oﬀ in a smooth, monotonically
decreasing fashion. This choice is based on the assumption
that probe signals of immediate neighbors are more
predictive than more distant probes. A graphical repre-
sentation of the ﬂattop Gaussian function is shown in
Figure 2. The function gi(x) is deﬁned as:
giðxÞ¼Ifx    i1g  e
 ðx  i1Þ2
2 2 þIfx  i2g  e
 ðx  i2Þ2
2 2 þIfx2½ i1, i2 g 3
The variables  i1 and  i2 represent the mapped genomic
start and end position of the probes and   determines the
width of the kernel function. I is the indicator function
deﬁned as:
Ifbg ¼
1i f b is true
0 otherwise
 
4
Set Mi theoretically contains all probes on the same
chromosome as x, as they all contribute to sample point x.
To reduce computational load we only consider probes
that lie 4  upstream and downstream from sample point
x. In this range, 99.8% of the kernel surface is contained
and the error for not including kernels further up- or
downstream is negligible. To correct for boundary
problems at the chromosome ends and the centromeres,
the probes up to half the kernel width from the boundary
are mirrored.
It should be noted that the KSE of the aCGH ratio at
a clone position is the result of information gathered
along two dimensions: (i) information from all tumors
is incorporated through cross-tumor averaging and
(ii) information from neighboring clones is incorporated
through local regression.
The statistical signiﬁcance of the peaks found in the
KSE was determined by testing against a null distribution
of peak heights acquired from the KSEs obtained from
several random within-tumor permutations of the original
data (Figure 1c). The P-value is corrected for multiple
testing using a Bonferroni approach by multiplying the
resulting P-value by the number of peaks tested, thus
controlling the family-wise error (26). Combining the
threshold found by permutation with the KSE produces
the result visualized in Figure 1d. All regions where
the KSE exceeds the signiﬁcance threshold (red line) are
signiﬁcantly aberrant across the tumors, for a speciﬁc
kernel width.
Biologically, CNAs are found in a large variety
of shapes and sizes, from small ampliﬁcations to whole
chromosome loss due to uneven mitotic chromatid
separation. It is desirable to detect both large and small
aberrations. Furthermore, the strength of gain or loss is an
important factor, as high-level gains may reﬂect strong
oncogene activation and high-level losses may reﬂect
homozygous deletion of tumor suppressor genes. Diﬀerent
kernel widths must be used to ﬁnd both very localized,
high-level and low-level CNAs that span a large region.
The width of the kernel function will determine how broad
the region will be across which a probe amplitude will
inﬂuence the KSE, i.e. how much the kernels will overlap.
A narrow kernel can be expected to detect small local
aberrations, which will be smoothed away by a wide
kernel. Conversely, a wide kernel will identify long
aberrations of low to medium strength such as a single
copy loss or gain of a chromosome in a fraction of
the tumor cells, while missing localized aberrations. By
applying KC-SMART to a dataset using diﬀerent kernel
widths, we can construct a scale space of the dataset which
gives a comprehensive view of the aberrations in the
dataset. Another advantage of the scale-space analysis is
that within a single aberration multiple levels of CNA may
be present. Analyzing these aberrations using multiple
scales can identify the region within an aberration that is
signiﬁcant across scales, and therefore more interesting.
A visualization of how the scale space is constructed is
depicted in Figure 1e.
A typical recurrent aberrant region is several megabases
long and may contain many genes. To ﬁlter the genes in
a recurrent region identiﬁed by KC-SMART we use gene
expression measurements of the genes in those regions.
When the gene expression of a gene within a recurrent
CNA correlates well (P<0.05, Bonferroni corrected) with
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Figure 2. Main properties of the ﬂat top Gaussian function The BAC
clone is depicted as a red rectangle. The amplitude of the kernel is
determined by the summed log2 value of that BAC clone across all
tumors. The red line is a representation of gi.
PAGE 5 OF 16 Nucleic Acids Research, 2008, Vol. 36, No. 2 e13the average aCGH proﬁle of all probes within the region,
we consider it as an interesting candidate gene.
Validation ofKC-SMART
We applied KC-SMART to a publicly available dataset
of 89 human breast cancer samples for which both
aCGH data and gene expression data were available
(22). The results of the KC-SMART analysis are shown
in Figure 3. As is immediately apparent, these tumors are
characterized by a larger number of recurrent losses as
opposed to recurrent gains. Whole chromosome arm
aberrations, such as the well-known 1q and 8q gains and
17p loss are found to be signiﬁcantly recurrent (27,28).
Also smaller, local aberrations are identiﬁed such as the
17q ampliﬁcation of the ERBB2 gene and the gain of the
11q region containing cyclin D1.
To test the biological relevance of the results, we
assessed the enrichment for known cancer genes among
the signiﬁcantly correlating genes located in the signiﬁ-
cantly recurrent regions. (See the Methods section for the
determination of signiﬁcantly correlating genes.) We used
the hypergeometric test to assess signiﬁcant enrichment.
As ‘known’ cancer genes, we used the Cancer Gene Census
(CGC) (29). More speciﬁcally, we tested genes in gains
against the CGC dominant genes and the genes in losses
against the CGC recessive genes. We used the dominant/
recessive terminology from the Futreal et al. (29) paper
which is not synonymous with the classical genetic
deﬁnition of dominant and recessive alleles, but rather is
a crude separation between oncogenes and tumor sup-
pressor genes. As shown in Table 1, both KC-SMART
analyses show signiﬁcant enrichment for CGC genes
(P<0.05).
As an alternate test we explored the association of the
genes in the various lists to cancer using the Genetic
Association Database (geneticassociationdb.nih.gov/).
Their association with the ‘cancer’ category was deter-
mined using the DAVID Bioinformatics Resources (24).
As shown in Table 1, the KC-SMART results also show
a signiﬁcant association with cancer (P<0.05) for this
database.
In order to extend our biological validation of the
data, we determined whether regions found signiﬁcant by
KC-SMART were associated with molecular breast
cancer subtypes (30). For each tumor in the 89 tumor
Figure 3. Results of KC-SMART analysis of 89 human breast tumor samples. The human tumor set was acquired from Chin et al. (22). Signiﬁcant
recurrent regions found by KC-SMART are shown in green. Signiﬁcantly correlating genes from the Cancer Gene Census (CGC) list are shown
below for each result. The cancer gene census list was split in CGC dominant genes (for gains) and CGC recessive genes (for losses). Black dotted
lines represent the end of chromosomes; magenta dotted lines represent the centromere location.
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based on gene expression proﬁles. To determine which
tumors contribute to a certain signiﬁcant aberration,
we ranked the tumors based on their average log2 value
across all BAC clones in the aberrant region. Next, we
calculated the cumulative contribution of the top n tumors
to the total average log2 value in the aberrant region.
The top n tumors, for which the cumulative contribution
reached 75%, were marked as signiﬁcantly contributing to
that aberration. The threshold of 75% is chosen to be
a conservative estimate, to ensure that all tumors truly
contain this aberration. Among the tumors that contribute
to a certain aberration we calculated the enrichment
for each molecular subtype using the hypergeometric
distribution. As can be seen in Tables 2 and 3, this analysis
reveals signiﬁcant association of several well-known
aberrant regions with distinct molecular subtypes (22,31)
and clinicopathological features.
Three regions with interesting associations were selected
and summarized in Table 4. One of these regions is the 5q
loss, which is associated with the basal-like breast cancer
subtype and ER, PR and ERBB2 negative status.
Basal-like breast tumors are known to have a low
frequency of ER and PR expression, and rarely over-
express ERBB2 (32). Similarly, a gain on chromosome 16p
can be considered a marker for ER and PR positive
tumors and the Luminal A subtype (28). The loss on 9p is
most common in normal-like tumors, which are associated
with a genomically stable diploid genotype (33). This
region contains the well-known tumor suppressor
CDKN2A (p14
ARF). CDKN2A gene expression was also
found to signiﬁcantly correlate with the 9p CNA proﬁle,
and can therefore be considered a putative driver gene for
this location. These results show that association studies
with regions detected by KC-SMART not only recapitu-
late known associations (5q, 16p) but also identiﬁes
potential new associations (9p).
The classical way of analyzing aCGH data is to produce
frequency plots. This approach counts the frequency of
occurrence of probes called as gained, lost or unchanged.
The method of calling varies from setting a rough
threshold on the raw data to applying dedicated segmen-
tation and calling algorithms. To compare KC-SMART
results to frequency-based analyses we employed a
Table 1. Enrichment of correlating genes found by KC-SMART for known cancer genes
Cancer Gene Census Enrichment Number of genes in gene set
a Number of CGC
b genes in gene set P-value enrichment for CGC
b genes
c
KC-SMART gains
  521 17 0.0213
KC-SMART losses
  590 9 0.0006
DAVID analysis Number of correlating genes
d Number of cancer genes P-value association with cancer
category (EASE score)
KC-SMART gains
  529 13 0.021
KC-SMART losses
  609 11 0.046
 Gene sets marked with an asterisk showed signiﬁcant enrichment for cancer genes at P<0.05.
aNumbers of genes were based on genes that had an Ensembl ID.
bCancer Gene Census.
cCalculated using the cumulative density function of the hypergeometric test. Total number of genes in the genome used for this analysis: 11409,
total number of dominant CGC genes: 275, total number of recessive CGC genes: 65.
dNumbers of genes were based on genes that had an Entrez ID.
Table 2. Association of KC-SMART signiﬁcant regions to the ﬁve breast cancer subtypes (30)
For each subtype the signiﬁcantly enriched aberrations are listed. Signiﬁcance was determined using the hypergeometric distribution and corrected
using Benjamini–Hochberg multiple testing correction. Locations mentioned in the start and end column are accurate up to maximally 1Mb, as this
is the resolution of the array.
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provided by J. Fridyland. These data have been discretized
with discretization algorithms, such as CBS (25) and
MergeLevel (13). The results of our comparison are shown
in Figure 4.
Figure 4a shows a genome-wide view of the frequency
of alterations compared to the KC-SMART results for a
single kernel width. Since most researchers use a frequency
cutoﬀ between 25 and 35% to deﬁne interesting regions
(31,34–36), we chose a cutoﬀ of 30% to deﬁne signiﬁcant
regions in the frequency analysis. The right panel shows
the result for chromosome 17. It can be seen that by
employing a smaller kernel width, KC-SMART detects
the ERBB2 ampliﬁcation, which is not picked up by the
frequency analysis. The overlap between the number of
probes in the signiﬁcant regions for KC-SMART
(P<0.05) and the number of probes in regions aberrated
in  30% of the tumors is shown in Figure 4b. The Venn
diagrams show that there is a large overlap in the copy
number losses identiﬁed by both methods, but that the
frequency method ﬂags a larger number of probes as
gained. To determine whether KC-SMART underesti-
mates the number of signiﬁcant regions or whether the
frequency method overestimates the number of aberrated
regions, we used the aCGH data to assess the ‘quality’
of the identiﬁed regions. More speciﬁcally, we computed,
for each identiﬁed consecutive region, all the pair-wise
correlation coeﬃcients of clones within that region.
Our hypothesis is that a higher degree of correlation will
be indicative of a better delineation of the aberration.
The smoothed histograms for both KC-SMART and the
frequency approach are depicted in Figure 4c, As can be
seen, the within-region correlation coeﬃcients are, on
average, much higher in the gained regions detected by
KC-SMART than in the regions detected by the frequency
approach. The frequency approach performs similar to
KC-SMART when looking at the lost regions.
To our best knowledge, the only other readily available
method that incorporates a statistical framework
for multiexperiment aCGH analysis is STAC (17). This
method employs two statistics, the frequency statistic and
the footprint statistic, to identify aberrant regions. STAC
requires aCGH data to be discretized to contain only
1 (gain),  1 (loss) and 0 (no change). We analyzed the
same 89-sample breast cancer dataset using STAC.
Results are shown in the Supplementary Data. When
comparing the regions found signiﬁcant by both methods
it is striking that STAC does not identify the 1q arm gain
or the 17q ERBB2 ampliﬁcation as signiﬁcant. Signiﬁcant
regions found by STAC seem to aggregate at boundaries
Table 3. Association of KC-SMART signiﬁcant regions to the ﬁve breast cancer subtypes (30)
For each clinical parameter the signiﬁcantly associated aberrations are listed. Signiﬁcance was determined using the hypergeometric distribution and
corrected using Benjamini–Hochberg multiple testing correction8. Locations mentioned in the start and end column are accurate up to maximally
1Mb, as this is the resolution of the array.
 The 5q loss associated with PR-negative staining was included as it was the most signiﬁcant association with PR-negativity and only borderline
not-signiﬁcant.
Table 4. Summary of association for three recurrent regions identiﬁed from 89 human breast tumors
Aberration Subtype ER PR ERBB2 P53 mutated
b
5q loss (53Mb–138Mb) Basal neg neg
a neg pos
16p gain (0Mb–10Mb) Luminal A pos pos neg neg
9p loss (0Mb–25Mb) Normal-like N/A N/A N/A N/A
pos: signiﬁcant association with positive immunohistochemistry (IHC), neg: signiﬁcant association with negative IHC, N/A is used when no
signiﬁcant association was used.
aThis association was identiﬁed as borderline signiﬁcant, but was the most signiﬁcant association found for PR-negative status.
bAs determined by immunohistochemistry.
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algorithm for boundary regions. To investigate the nature
of the signiﬁcant regions detected by STAC but not by
KC-SMART, we analyzed the raw log2 values and
compared them to the discretized values produced by
Chin et al. (22). Two examples of this analysis are shown
in the Supplementary Data. Generally, the areas exclu-
sively detected by STAC are scored as single copy
alterations by the MergeLevels analysis done by Chin
et al. (22). On a log2 scale these gains and losses were very
small indeed ( 0.1), but nevertheless large enough to be
assigned a value of 1 or  1, and are therefore treated
equally to large gains and losses. This discrete approach,
which neglects the amplitude of an aberration can
therefore be considered to be less conservative than
KC-SMART and can/may therefore yield more false-
positives.
Cancer genediscovery using KC-SMART
To identify genes that are associated with CNA and
potentially implicated in tumor formation we applied
KC-SMART to a dataset containing aCGH measure-
ments of 19 mammary carcinomas acquired from condi-
tional p53 knockout mice. Sporadic mammary tumor
development in these mice is induced by cell type-speciﬁc
stochastic inactivation of the tumor suppressor gene p53
(37). Mouse mammary tumors present with relatively
few passenger mutations as compared to human sporadic
tumors. This is because tumors from genetically
engineered mouse models have a more uniform cell type
of origin and they develop relatively rapid giving less time
for passenger CNA development. This will aid in
identiﬁcation of causal aberrations and will reduce the
number of tumors required for cancer gene discovery.
Mouse aCGH data were preprocessed as described in the
Methods section. The result of the analysis is shown in
Figure 5. In total, seven ampliﬁed and 11 deleted regions
were identiﬁed by KC-SMART.
The signiﬁcant CNAs identiﬁed by KC-SMART are
large and contain many genes. Oncogenic aberrations
typically occur because it is the mechanism through
which an oncogene is ampliﬁed or a tumor suppressor
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of all tumors to ﬁnd the genes which are driving the
aberrations. We used an in-house 32-k oligonucleotide
microarray platform with 31769 longmer probes targeting
19104 unique genes, which is 68% of the known mouse
protein-coding genes. By analyzing only the genes that are
measured on the array, we accept the possibility of missing
the driver gene because there is no corresponding probe on
the array. Furthermore, the gene expression data were
obtained using a pool of 12 mouse mammary tumor
samples as a common reference. While these measure-
ments will reveal the within-group variability of the tumor
dataset, genes that are over-expressed or downregulated in
all tumors will not be picked up, because their RNA levels
in the reference pool are the same. The complete results of
these analyses can be found in the Supplementary Data.
As can be seen in Table 5 and Figure 6 the correlation
analysis resulted in association of several known and
novel cancer genes with signiﬁcant recurrent CNAs. Our
correlation analysis resulted in the association of three
known cancer genes with gained regions (Ptpn11–Chr. 5,
c-Met–Chr. 6 and Birc2–Chr. 9) and one known cancer
gene within a deleted region (Cyld–Chr. 8). The mouse
homologs from the CGC were used as ‘known’ cancer
genes. The identiﬁcation of known cancer genes validates
this approach for cancer gene discovery.
Novelcandidate cancer gene discovery
Correlation analysis can also be used for the identiﬁcation
of new cancer gene candidates. In addition to the purely
data-driven approach, the candidate genes were further
analyzed based on known functionality and possible links
to carcinogenesis. The possibility exists that a gene with
an unknown function could be a driver gene, and it will be
missed by this approach. Keeping this in mind, one should
reconsider these genes when no obvious candidate is
found, or when validation experiments do not show any
causal role for the identiﬁed candidate genes.
Chromosome 8 gain. None of the 22 genes identiﬁed
by correlation analysis are listed in the CGC. Based on
previous studies we identiﬁed four possible candidates:
Cdc16, Tfdp1, Cul4a and Fboxo25 (38). The human
homolog of Cdc16, a subunit of the anaphase promoting
complex which governs degradation of G1 checkpoint
proteins, has also been linked to cancer (39). Tfdp1 is
a transcription factor that operates in concert with the
E2F family to upregulate genes associated with cell cycle
progression (40). Cul4a is a ubiquitin ligase that targets
the cyclin-dependent kinase inhibitor p27 for degradation
and thereby Cul4a activity promotes proliferation and cell
cycle progression (41). Fboxo25 is a member of the F-box
only protein family (42), which is well known for their
ubiquitin-ligase function.
Chromosome 18 gain. None of the seven genes identiﬁed
by correlation analysis are listed in the CGC. Only one
gene was found to have interesting functional annotation:
Rfn138. The human homolog of Rnf138, dubbed NARF,
has recently been identiﬁed as a ubiquitin ligase targeting
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Figure 5. KC-SMART results on the p53-deﬁcient mouse model
mammary tumors. The y-axis represents the interpolated scale space
running from 2 to 40Mb. Black dotted lines represent the end of
chromosomes.
Table 5. Overview of the regions found by KC-SMART analysis of
the mouse conditional p53 knockout dataset
Chromosome Position
(Mb)
Number
of
correlating
genes
Correlating
cancer
genes
1
Candidate
cancer genes
Gains
5 100–151 48 PTPN11 –
6 3–26 9 C-MET –
8 3–15 22 – CDC16, TPDF1,
CUL4A, FBOXO25
9 6–15 7 BIRC2 –
11 114–118 9 – BIRC5
15 52–102 0 – –
18 10–26 7 – RNF138
Losses
1 37–40 2 – GNT-IVA
4 91–103 0 – –
4 122–133 0 – –
7 72–85 4 – –
7 131–134 3 – BUB3, BCCIP
8 23–131 37 CYLD –
10 112–129 10 – USP15
11 37–75 29 – HINT1, RAD50,
IRF-1
12 4–117 10 – NUMB
14 54–83 1 – –
18 55–83 1 – –
The positions mentioned are based on the maximal width of the
aberration found across all scales. Genes that either have a start or end
position in the region were taken into account. Only genes against
which an oligonucleotide probe was present on the gene expression
micro-array platform were considered. The last column shows new
likely cancer gene candidates, based on the result of the correlation
analysis (Pearson correlation, P<0.05, Bonferroni–corrected) and
based on functional analysis. When no likely candidates were found
in the correlating genes based on functional analysis, none were listed.
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Wnt-signaling target genes (43). Derepression of Wnt
target genes due to loss of TCF/LEF might promote
tumorigenesis.
Chromosome 7 loss. Of the three genes found by
correlation analysis, two were interesting candidate
cancer genes. Bub3 is a mitotic spindle checkpoint gene
that can act as a repressor of cell cycle progression (44).
Deletion of this gene could enhance cell cycle progression
and thus proliferation. Bccip is a BRCA2 interacting
protein and has been found to be important in double-
strand break repair (45). Loss of Bccip might lead to
genomic instability and thus enable tumorigenic
aberrations.
Chromosome 10 loss. Of the 10 genes found by correlation
analysis, only one gene, Usp15, had functional annotation
that could be related to tumor suppressor activity. Usp15
has recently been found to be present in the COP9
signalosome, which is an important regulator of ubiquitin
ligase activity and has been implicated in cancer (46,47).
It should be noted that the chromosome 10 region includes
several cancer genes, including the known tumor suppres-
sor Ddit3, also known as CHOP. CHOP expression
correlated just below the signiﬁcance threshold set for
correlation analysis.
Scale spaceaided aberration analysis
Our correlation analysis did not yield promising cancer
genes for each region. For example, the chromosome
15 copy number gain is a large aberration found by
KC-SMART and spans around 50Mb over all scales
analyzed. Yet, no cancer gene candidates were identiﬁed
using the correlation approach. Since the chromosome
15 gain is analogous to the human chromosome 8q,
we expect the oncogene Myc to be the target of the
ampliﬁcation. The Myc oncogene is a well-known target
of DNA ampliﬁcation in human cancer (48,49).
We therefore set out to analyze the chromosome 15 gain
with the aid of the scale space. The scale space of mouse
chromosome 15 identiﬁes a large region as signiﬁcant in
the large scales, yet only a small region remains signiﬁcant
in the smaller scales (Figure 7a). If this region is analyzed
in more detail (Figure 7b) one can see several genes
situated next to the narrow signiﬁcant region. The two
genes that directly map onto the signiﬁcant region
are both predicted transcripts with unknown function.
The Myc oncogene is situated slightly upstream from the
signiﬁcant region. If the heatmaps of the BAC clones are
examined (Figure 7d) it is apparent that BAC Clone
7 shows a gain in multiple tumors. This could indicate that
ampliﬁcation of the region downstream of Myc has
a tumorigenic eﬀect, either by aﬀecting Myc in some
way or acting on a previously unknown gene. It could also
mean that the chromosome 15 gain is not directed at the
Myc oncogene, but rather at the Ddef1 gene. Ddef1 has
been identiﬁed as a pathologically relevant target of
ampliﬁcation in human uveal melanoma (50). This result
shows that scale-space analysis can be eﬀectively used to
gain more insight in complex aberrations and to identify
potential target genes.
Besides giving more insight in the nature of aberra-
tions, the scale space is also used to identify both small
focal aberrations and large low level CNAs such
as chromosomal gains or losses. The smaller scales allow
for identiﬁcation of high-level ampliﬁcations, such as
the ERBB2/HER2 ampliﬁcation in human breast
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Figure 6. Expression and genomic proﬁles of the known cancer genes and the cancer gene candidates discovered in p53-deﬁcient mouse mammary
tumors. For each aberration the chromosome number is given as well as the average aberration BAC proﬁle of the BAC clones in the aberrant
region. The gene expression proﬁles of the genes that were selected based on their correlation with the BAC proﬁle are depicted below each BAC
proﬁle. Green indicates downregulation/loss, red indicates overexpression/gain.
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is found to be signiﬁcant in the smaller scales, but it is
smoothed away in the larger scales. Conversely, a large
systemic loss of chromosome 9p containing the INK4a/
ARF tumor suppressor locus is only detected as signiﬁcant
in the highest two scales analyzed (Figure 7g). By
traversing the scale space we can ﬁnd biologically relevant
aberrations of all sizes.
DISCUSSION
Genomic instability is a powerful, yet chaotic way of
acquiring aberrations that confer proliferative or survival
advantages to a tumor cell. Correctly separating driver
mutations from passenger mutations in aneuploid tumors
is very diﬃcult. The classical tumor model assumes clonal
expansion of a tumor from a single progenitor cell;
however, recent views on tumor development preferen-
tially model the tumor as an ecological model, with
diﬀerent populations of tumor cell clones competing for
survival (19). In such a diverse population of tumor cells,
CNA should also be diverse. As an aCGH measurement is
an averaged view of all CNAs within a large heterogenic
population of tumor cells, discretization of these values to
integer levels of copy number change may result in loss of
information, which is exempliﬁed by the fact that the level
of ERBB2 ampliﬁcation is a determinant of breast cancer
progression (51). KC-SMART is the ﬁrst method to
use nondiscretized data to ﬁnd statistically signiﬁcant
recurrent CNAs. KC-SMART uses the log2 values
straight from the aCGH platform and is therefore
not dependent on preprocessing steps, except for data-
normalization. We show that relevant biological data are
contained in the continuous log2 aCGH measurements.
So, instead of noise reduction, discretization may well
cause information loss. We think that approaches that
discretize the aCGH data prior to detecting CNAs are
likely to perform very well in clonal systems, such as cell
lines and hematological tumors. KC-SMART is preferable
for analysis of aCGH data from more heterogeneous
solid tumor samples.
Tumor tissues are challenging biological samples and
their copy number analysis is confounded by several
factors. Stromal contamination will quench the signal by
introducing normal 2n DNA in the sample. Very pure
(clonal) tumors will have a larger eﬀect on the analysis as
their overall measured copy number levels are higher.
Both discretization approaches and KC-SMART will be
Figure 7. Scale-space analysis of the chromosome 15 aberration. (a) Scale-space analysis of the complete chromosome. The outer black dotted lines
denote the end of the chromosome. The inner black dotted lines denote the area shown in (b). (b) Zoom-in view of the scale-space analysis of
chromosome 15. The BAC clones that are mapped to this region are shown as blue blocks. The genes that are situated in this region are depicted
as red blocks. (c) Genes close to the region that is signiﬁcant across all scales are shown in more detail. (d) This ﬁgure shows the heatmap of the
BAC-clones shown in (b). Numbers along the horizontal axis correspond to the BAC clone numbers in (c). Positive log2 values as shown as red,
negative log2 values as green. (e) Heatmap of the gene expression of genes Myc, Ddef1 and Adcy8. Note: The tumors are now depicted along the
horizontal direction, as opposed to (d), where the tumors are depicted in the vertical direction. Positive log2 values as shown as red, negative log2
values as green. No probe against Pvt1 was present on the gene expression array. The two unknown-function transcripts overlapping with BAC clone
7 show equally uncorrelated expression proﬁles, and are denoted by I and II. (f) This ﬁgure shows a scale-space analysis of signiﬁcant gains on
chromosome 17. The analysis is from a set of 89 human breast tumors. (g) A scale-space analysis of chromosome 9 losses. The analysis is from a set
of 89 human breast tumors.
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will employ the measured aberration level in the analysis,
discretization approaches will, depending on the chosen
discretization threshold, either fully count an aberration
(regardless of the degree to which it exceeds the threshold)
or completely discard a probe when the CNA signal
does not exceed the threshold deﬁning an aberration.
Very large focal ampliﬁcations will be maintained in the
KC-SMART analysis, but if a suﬃciently large set of
tumors is analyzed, these aberrations will not be ﬂagged as
signiﬁcant, unless they appear with suﬃcient frequency.
Random signal noise is always a confounding factor in
aCGH data analysis. Especially formalin ﬁxed paraﬃn
embedded (FFPE) samples are known to produce noisy
measurements, making aCGH data from these samples
hard to analyze. Since KC-SMART analyzes gains and
losses separately, the possibility exists that noise which
randomly ﬂuctuates around zero will be detected as
aberrations due to the separation of data in positive and
negative values. However, this is countered in the random
permutation scheme where all values including random
ﬂuctuations are incorporated in the construction of
the background distribution. By determining a null-
distribution for each dataset analyzed, noise speciﬁc to
that dataset is modeled and therefore also controlled.
To gain the most power from an analysis we encourage
researchers to keep comparable noise levels across the
entire dataset.
We showed association of recurrent aberrations found
by KC-SMART with molecular subtype (30) or clinico-
pathological features such as p53, ERBB2, estrogen
receptor (ER) and progesterone receptor (PR) expression
status. Identiﬁcation of the previously reported 16p and
5q regions show that known relations are recapitulated by
KC-SMART, and that these regions might be markers for
the Luminal A and basal-like breast cancer subtypes,
respectively. The 5q loss is an important feature employed
in a classiﬁer to separate BRCA1-mutated breast cancers
from control tumors (52). BRCA1-mutated breast tumors
are known to be generally basal-like (53), and the fact
that aberrations on chromosome 5q can distinguish the
BRCA1 tumors from control tumors is possibly due to
their basal-like character. A BRCA1-modiﬁer locus for
hereditary breast cancer has been mapped to 5q (54) and
multiple DNA-damage repair and cell cycle associated
genes are present in the 5q region (e.g. RAD50, RAD17,
APC). This ﬁnding might point to a more general DNA
damage-related phenotype in basal breast tumors.
Other relations with regions identiﬁed by KC-SMART
are new, such as the association of 9p loss with normal-
like tumors, which could target the well-known INK4a/
ARF tumor suppressor locus located on 9p21. In a large
clinical study, normal-like tumors were found to be mainly
diploid, genomically stable tumors (33). In line with this,
mouse mesotheliomas induced by Nf2 and Ink4a/Arf
loss show signiﬁcantly less genomic instability than
mouse mesotheliomas induced by Nf2 and p53 loss
(van Montfort,E. and Berns,A., unpublished data).
Normal-like tumors may thus be driven by INK4a-ARF
loss-of-function.
Array CGH data analysis can result in detection of
large regions containing many genes. The application of
KC-SMART in combination with gene expression micro-
array data facilitates prioritization of genes for biological
validation. While there are many (epi)genetic mechanisms
through which a tumor can upregulate oncogenes or
downregulate tumor suppressor genes, it has been shown
that CNAs can predict gene expression (55). Nevertheless,
one should be aware of the risk of missing important genes
that do not seem to correlate very well with the copy
number data.
Our results obtained from the KC-SMART analysis
combined with gene expression data of the p53 conditional
knockout mice did reveal some well-known cancer genes
that have been associated with CNAs before. Two of the
seven genes that are identiﬁed by the correlation analysis
on chromosome 9 were previously implicated in tumor-
igenesis: Birc2 and Birc3 (56). Birc2 is also listed in
the CGC list. Both are members of the cIAP family of
antiapoptotic caspase-binding proteins. Zender et al. (56)
demonstrated the tumorigenic eﬀect of Birc2 in Myc
overexpressing cells. Their comparative oncogenomics
approach uses CNA information to ﬁnd potential
oncogenes and tumor suppressors. As human data are
inherently complex, cross-species analysis can provide
additional power to identify truly causal genes. CNA
detection is an increasingly valued tool in cross-species
oncogenomics (57). KC-SMART would be ideally suited
to provide the ﬁrst analysis of CNAs in a comparative
oncogenomics study.
The examples of Birc2/3 and other known cancer genes
identiﬁed by correlation analysis show that biologically
relevant results can be obtained using this approach.
However, not every region delivered a promising cancer
gene candidate after correlation analysis. Especially, the
lost regions did not produce many obvious candidates,
because the correlation analysis either delivered very many
or very few genes. This could point to the fact that
a tumor cell might be more inclined to use epigenetic
factors to downregulate tumor suppressor genes so that
the correlation between expression and copy number
values would be disturbed. It could also mean that
a deletion is more suited to incur haploinsuﬃency of
large numbers of genes, which may collectively contribute
to tumor development (58). In contrast, ampliﬁcation is
more likely to result in overexpression of one or a few
genes which are therefore more likely to be detected by
correlation analysis.
The scale space provided by KC-SMART facilitates
analysis of complex aberrations. As our scale-space
analysis of the chromosome 15 aberration in the mouse
p53-deﬁcient mammary carcinoma dataset shows, true
targets of gains and losses can be determined. Of course,
this analysis is spatially restricted to the resolution of the
aCGH platform and quantitatively restricted to the degree
with which individual probes on the microarray report
CNAs. We foresee that the scale-space analysis will allow
a very insightful and accurate determination of aberrant
regions across multiple tumors.
We sought to compare our results to those obtained
by existing methods. First we compared our approach to
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analyze aCGH data. We used the discretized version of the
Chin et al. data, as discretized by the authors, using two
diﬀerent algorithms to obtain segmented and called data.
Our method compares favorably to this more complicated
approach. One intrinsic problem associated with fre-
quency analysis is that it is mainly descriptive. There is no
statistical basis for calling a region signiﬁcantly recurrent
aberrated. KC-SMART provides the researcher with
a solid statistical analysis, while frequency-based thresh-
olds will be arbitrarily chosen. Furthermore, KC-SMART
has the added advantage of incorporating a scale-space
analysis. The advantages of this feature have already been
clearly demonstrated in the example where KC-SMART
can readily identify high-level amplicons, while frequency-
based methods need additional adaptations to detect
these ampliﬁcations.
To the best of our knowledge, the only method
that encompasses a statistical framework and has readily
available software to perform multiexperiment aCGH
data analysis is STAC (17). Several remarks can be made
on the comparison between STAC and KC-SMART.
STAC results are dependent on the manner in which the
two STAC statistics are combined. Results for both the
statistics (footprint and frequency) can be very diﬀerent.
This disparity complicated the interpretation and might
lead to results-oriented use of statistics. Furthermore,
STAC bases the background-distribution of their statis-
tical tests on local chromosome-arm permutation. This
means that recurrent loss or gain of whole-chromosome
arms cannot be detected. A prime example of this is the
well-known gain of human 1q which was not identiﬁed
as statistically signiﬁcant by STAC. Also, basing the
background distribution just on the chromosome arm is
not a correct representation of the biological reality,
where the exact position of a gain or ampliﬁcation is not
known and could be located on a completely diﬀerent
chromosome arm. To get a better average background
distribution, permutation over the entire genome is
preferable.
In summary, we have developed the ﬁrst parameter-free
statistical method to ﬁnd signiﬁcantly recurrent CNAs
from continuous aCGH measurements. In contrast to
other approaches, KC-SMART inputs nondiscretized
data, which minimizes loss of information and enables
better modeling of the continuous-valued amplitude of
CNAs. KC-SMART employs a permutation approach to
detect statistically signiﬁcant CNAs while keeping control
of the error rate. A scale space is constructed which
facilitates detailed inspection of CNAs at a range of
genomic resolutions. KC-SMART compares favorably to
existing aCGH analysis methods and produces biologi-
cally relevant results. Furthermore, using KC-SMART we
identify several new candidate cancer genes. DNA is the
static foundation of the dynamic cellular environment.
Tumor cells often resort to modiﬁcation of the DNA
content of the cell to further their proliferative and
survival strength. The ability to detect these changes will
help us understand the genetic basis of cancer, and it
allows us to prioritize our subsequent research into causal
components of tumor cells.
SUPPLEMENTARY DATA
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